Drug Resistance

Company Rates Efficacy of Next Generation Antibacterial Agents

Published in Vaccine Weekly, November 22nd, 1999

The continuing increase in the prevalence and diversity of drug-resistant strains of bacteria will drive development and sales of new antibacterial agents well into the future, a new study indicates.

Indeed, many clinicians and researchers believe that success in antibacterial therapy will always depend on a steady supply of new antibacterial drugs that are unaffected by prevalent resistance mechanisms.

Decision Resources, Inc., recently published a study, titled "Emerging Antibacterial Agents," that assesses the probable efficacy of many new agents (broad-spectrum antibacterials and drugs for serious Gram-positive infections) and gives an overview...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-11-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry